About Us

Oberland Capital, a private investment firm with over $1.2 billion in capital commitments since inception, is focused exclusively on investing in the global healthcare industry. We specialize in flexible investment structures customized to meet the specific capital requirements and strategic objectives of transaction partners. Our broad suite of financing solutions includes monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investment in debt and equity securities. With a combination of deep industry knowledge and extensive structured finance experience, the Oberland Capital team has a history of creating value for our transaction partners.

Approach

Oberland Capital targets investments globally in commercial stage or near-commercial stage biopharmaceutical, medical device and diagnostic products and companies. We focus on opportunities involving differentiated healthcare products developed or marketed by experienced management teams. Our target investment size ranges between $20 million and $150 million, with the ability to execute significantly larger transactions.

We partner with management teams to develop creative financing solutions that meet their specific needs. Our investments enable transaction partners to access capital to pursue a variety of objectives, including: accelerating R&D, expanding commercial infrastructure, acquiring new assets, and refinancing or supplementing existing capital sources. We excel in developing and implementing novel, non-dilutive transaction structures in situations involving significant complexity.

Royalty
Interests
Royalty Interests

Oberland Capital seeks to acquire royalty interests by providing capital up-front or in a series of performance-based milestones to royalty owners such as companies, universities, research institutions, and individual inventors. Royalty owners can immediately realize value from their healthcare-related royalties through our financing solutions. Monetizing all or a portion of existing or future royalty streams provides capital for uses such as funding research, expanding facilities, and diversifying portfolios.

Royalty-Backed
Securities
Royalty-Backed Securities

Oberland Capital targets investments in the form of structured loans that are collateralized by royalties, license agreements, and intellectual property. Principal and interest payments on the loan are derived solely from royalties received and are typically non-recourse to the royalty holder. Once the loan is repaid in full the royalty owner retains rights to all future royalties.

Revenue
Interests
Revenue Interests

Revenue interests are financial arrangements structured to function as royalty interests. Oberland Capital can provide capital upfront or in a series of performance-based milestones to healthcare companies that are actively commercializing products in exchange for a percentage of future revenues from one or more products. Revenue interest financing is non-dilutive to shareholders and typically involves a less restrictive set of covenants than traditional debt.

Traditional
Debt
Traditional Debt

In certain situations, Oberland Capital may make standalone investments in healthcare companies in the form of traditional debt or traditional debt in combination with preferred equity.

Project-Based
Structures
Project-Based Structures

Oberland Capital can provide financing to companies for the purpose of completing late-stage clinical trials. In this type of structure, Oberland Capital may receive milestone payments depending on the successful progress of the clinical trials plus non-contingent payments from royalty interests or revenue interests on existing commercialized products. This form of financing allows companies to accelerate R&D timelines and pursue a broader set of development projects.

Hybrid
Structures
Hybrid Structures

Oberland Capital seeks to employ structures combining traditional preferred equity or debt instruments with the purchase of passive royalties or revenue interests. These hybrid structures allow for tailored solutions to meet our transaction partner's specific capital requirements.

Royalty Interests

Oberland Capital seeks to acquire royalty interests by providing capital up-front or in a series of performance-based milestones to royalty owners such as companies, universities, research institutions, and individual inventors. Royalty owners can immediately realize value from their healthcare-related royalties through our financing solutions. Monetizing all or a portion of existing or future royalty streams provides capital for uses such as funding research, expanding facilities, and diversifying portfolios.

Team

Oberland Capital was founded in 2013 by Managing Partners Jean-Pierre Naegeli and Andrew Rubinstein, who have more than 25 years of combined experience in traditional and structured healthcare royalty investing and over 40 years of relevant healthcare-related structuring, licensing and operating experience.


The broader investment team has over 115 years of relevant healthcare and finance experience. The team possesses significant financial and operational expertise built throughout long tenures in the healthcare industry in a diverse array of senior management, principal investing, quantitative investing, investment banking, and consulting roles. Our knowledge base spans the pharmaceutical, biotechnology, medical device, and diagnostic sectors, and numerous therapeutic categories. The team's extensive experience in the United States, Europe and other territories allows us to effectively source, diligence, structure, and execute transactions across the globe.

Jean-Pierre
Naegeli

Managing Partner

Mr. Naegeli is a Managing Partner at Oberland Capital. Previously, he was a Partner at Paul Capital, a leader in healthcare royalty investing at the time. Prior to joining Paul Capital, Mr. Naegeli spent nearly a decade at Johnson & Johnson, initially in operational and corporate roles, including assessing healthcare technologies across all divisions, followed by five years in principal investing at Johnson & Johnson Development Corporation, the strategic investment and venture capital subsidiary of Johnson & Johnson. In addition, Mr. Naegeli has extensive engineering experience in Europe. He received a Masters in Public and Private Management from the Yale School of Management, and his Diploma in engineering from the Swiss Federal Institute of Technology.

Andrew
Rubinstein

Managing Partner

Mr. Rubinstein is a Managing Partner at Oberland Capital. Previously, he was a Partner at Paul Capital, a leader in healthcare royalty investing at the time. Prior to joining Paul Capital, he was CEO of Microban International, Ltd. a global licensing business focused on antimicrobial technologies. Mr. Rubinstein had previously worked as an investment banker in the Financial Sponsors Group at Merrill Lynch & Co. He earned a B.A. from the University of Pennsylvania, a J.D. from New York University School of Law, and an M.B.A. from New York University Stern School of Business.

William
Clifford

Partner

Mr. Clifford is a Partner at Oberland Capital. Previously, Mr. Clifford was an investment professional with Paul Capital where he was responsible for evaluating, structuring, executing, and managing healthcare royalty investments. Prior to joining Paul Capital, Mr. Clifford was an Associate at Health Advances where he led strategy consulting engagements for clients in the biotechnology, pharmaceutical, medical device, and diagnostics sectors. Previously, Mr. Clifford worked at Cap Gemini Ernst & Young's Center for Business Innovation. While attending graduate school, Mr. Clifford worked at In-Q-Tel where he evaluated biotechnology investment opportunities. Mr. Clifford received his M.S. in Biochemistry and Molecular Biology from Georgetown University and his B.A. from Kenyon College.

Cecilia
Gonzalo

Partner

Ms. Gonzalo is a Partner at Oberland Capital. Prior to joining Oberland, she was a Managing Director at Vatera Healthcare Partners, the venture capital and private equity investing arm of Vatera Holdings LLC, where she focused on investments in the biopharmaceutical industry. Previously, Ms. Gonzalo was a Managing Director with Essex Woodlands, a healthcare-focused growth equity firm. Ms. Gonzalo previously worked for 12 years in the healthcare group of Warburg Pincus LLC, a global private equity firm. Prior to her tenure at Warburg Pincus, Ms. Gonzalo worked at Goldman, Sachs & Co in the firm's Investment Banking Division and Principal Investment Area. Ms. Gonzalo currently serves as a board member and Co-President of the Harvard Business School Healthcare Alumni Association. Ms. Gonzalo earned an A.B. in Biochemical Sciences from Harvard College and an M.B.A. from Harvard Business School.

Michael
Bloom

Partner

Mr. Bloom is a Partner at Oberland Capital. Previously, Mr. Bloom was an investment professional at Paul Capital where he was primarily focused on evaluating and structuring healthcare royalty investments. Prior to joining Paul Capital, Mr. Bloom was a Consultant at the Frankel Group where he worked on due diligence, technology assessment and acquisition analysis for clients in the healthcare industry. Previously, Mr. Bloom worked with Innovative Health Solutions focusing on health economics and outcomes research. Mr. Bloom earned his M.B.A with honors from the Wharton School's Healthcare Management Program and his B.A. from Colby College.

Jesper
Wiklund

Managing Director, Europe

Mr. Wiklund is a Managing Director, Europe at Oberland Capital. Previously, he was the Chief Executive Officer of InDex Pharmaceuticals, a Swedish drug development company focused on the gastrointestinal market with an asset in phase III development. Prior to joining InDex he was responsible for Business Development at Swedish Orphan Biovitrum. Prior to that, Mr. Wiklund worked in the United States for Wyeth Pharmaceuticals and Elan Pharmaceuticals as well as in Germany for Evotec. Over the course of his career, Mr. Wiklund has completed strategic transactions with an aggregate value exceeding $1 billion and he has raised four rounds of Venture Capital from top-tier European Investors. He holds an M.B.A. from Harvard Business School and a B.S. in Biology from St. Mary's College of California. Mr. Wiklund is an employee of Wiklund Biotech Consulting.

David
Dubinsky

Chief Financial Officer

Mr. Dubinsky is the CFO at Oberland Capital. Prior to joining Oberland Capital, Mr. Dubinsky was a Managing Director and CFO at Siguler Guff & Company, a private equity firm with over $10 billion of assets under management. Mr. Dubinsky oversaw the accounting and client reporting functions of the Firm. Previously, Mr. Dubinsky was a Manager within the Assurance & Advisory Business Services department at Ernst & Young. Mr. Dubinsky holds a B.S. in Accounting from Binghamton University, a State University of New York, and is a Certified Public Accountant in the State of New York.

Johnna
Schifilliti

Director of Operations

Ms. Schifilliti is the Director of Operations at Oberland Capital. Previously, she was an Associate Director of Marketing in KPMG LLP's private equity practice. Ms. Schifilliti was responsible for the development and deployment of national private equity marketing programs including budget and strategic planning, credentials and collateral management, thought leadership development and execution, public relations, event planning and project management. Ms. Schifilliti began her career as an associate in KPMG's audit practice where she spent three years serving higher education and nonprofit clients. Johnna received a B.S. in Accountancy from Villanova University.

CN Chen,
CFA

Director of Quant Research

Mr. Chen is the Director of Quantitative Research at Oberland Capital. Previously, he was a Vice President in the Quantitative Research Group for JPMorgan Asset Management where he researched and developed systematic trading strategies for portfolios in Global Fixed Income, Currencies, and Commodities (GFICC) which manages approximately $500 billion in assets. Prior to that, he worked as a Research Analyst and Portfolio Manager focused on investments in structured products for Credit Renaissance Partners, a global distressed debt hedge fund. CN earned his M.S. in Mathematical Finance from New York University's Courant Institute and B.A.'s in Math, Economics, and Computer Science from Amherst College. He is a CFA charterholder.

Sarah
Siber

Vice President

Ms. Siber is a Vice President at Oberland Capital. Prior to joining Oberland, Ms. Siber was a Senior Manager in Corporate Development at Pfizer where she was responsible for evaluating and supporting the execution of the company’s strategic transactions, including M&A, licensing deals, and corporate level divestitures. Previously, Ms. Siber was an Investment Operations Analyst at The Blackstone Group within Blackstone Alternative Asset Management and an Investment Banking Analyst within the healthcare group at Oppenheimer & Co. Ms. Siber earned her M.B.A. from Columbia Business School and her B.S. in Operations Research & Information Engineering from Cornell University.

Greg
Certo

Associate

Mr. Certo is an Associate at Oberland Capital. Previously, Mr. Certo worked at Locust Walk, where he supported life sciences financing and strategic partnering transactions. Prior to joining Locust Walk, Mr. Certo worked at Health Advances, where he performed strategy consulting for clients in the biotechnology, pharmaceutical, medical device, and diagnostics sectors. Mr. Certo earned his M.B.A. from the Wharton School in the Health Care Management Program, and his A.B. from Dartmouth College.

Chelsea
McDonald

Executive Assistant

Ms. McDonald is an Executive Assistant at Oberland Capital. Previously, she was the Executive Assistant for the Founder & CEO of Innovation Department, a technology investment incubator. Ms. McDonald began her career in Sales Operations at TriNet and received her B.A. in Communications from University of Colorado at Boulder.

Contact



Oberland Capital Management



1700 Broadway, 37th Floor
New York, NY 10019

Phone: 212-257-5850
Fax: 212-257-5851
Email:
[email protected]